CANOPY GROWTH CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.37 CAD | +5.38% |
|
+5.42% | +66.86% |
| 02:14am | Canopy Growth Slides After Constellation Directors Leave, Share Conversion | DJ |
| Apr. 18 | Stocks to Watch : Canopy Growth, Metropolitan Bank, Netflix | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +66.86% | 715M | C- | ||
| +40.29% | 6.16B | B- | ||
| -15.73% | 4.49B | C+ | ||
| -9.40% | 3.17B | B- | ||
| -1.60% | 3.01B | C | ||
| -1.23% | 2.57B | - | D+ | |
| +34.89% | 1.8B | - | ||
| -11.37% | 1.62B | - | - | |
| -5.02% | 1.56B | - | - | |
| -13.21% | 1.53B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WEED Stock
- Ratings Canopy Growth Corporation
